KRONOS BIO INC (KRON) Forecast, Price Target & Analyst Ratings
NASDAQ:KRON • US50107A1043
0.88 USD
+0.01 (+1.49%)
Last: Jun 20, 2025, 08:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KRONOS BIO INC (KRON).
Forecast Snapshot
Consensus Price Target
$2.30
+ 160.80% Upside
Next Earnings Forecast
Release DateAug 6, 2025
PeriodQ2 / 2025
EPS Estimate-$0.21
Revenue Estimate
ChartMill Buy Consensus
82.86%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$2.30
Upside
+ 160.80%
From current price of $0.88 to mean target of $2.30, Based on 7 analyst forecasts
Low
$2.27
Median
$2.30
High
$2.36
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
7 analysts have analysed KRON and the average price target is 2.3 USD. This implies a price increase of 160.8% is expected in the next year compared to the current price of 0.88.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
KRON was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about KRON.
In the previous month the buy percentage consensus was at a similar level.
KRON was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-11-14 | TD Cowen | Downgrade | Buy -> Hold |
| 2024-11-14 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-10-08 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-08-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-12-19 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-12-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-04-17 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-18 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-10 | Goldman Sachs | Maintains | Buy |
| 2022-11-09 | Piper Sandler | Maintains | Overweight |
| 2022-09-14 | Berenberg | Initiate | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
| 2022-02-28 | Piper Sandler | Maintains | Overweight |
| 2021-11-10 | HC Wainwright & Co. | Maintains | Buy |
| 2021-06-24 | HC Wainwright & Co. | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateAug 6, 2025
PeriodQ2 / 2025
EPS Estimate-$0.21
Revenue Estimate
Revenue Q2Q-100.00%
EPS Q2Q20.67%
Number of Analysts5
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
KRON is expected to report earnings on 8/6/2025. The consensus EPS estimate for the next earnings is -0.21 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.288M | 9.848M 56.62% | -100.00% | 15.3M | 45.9M 200.00% | 71.4M 55.56% | 96.9M 35.71% | 122.4M 26.32% | |||
| EBITDA YoY % growth | -134.85M 9.75% | -115.065M 14.67% | -61.716M 46.36% | -92.79M -50.35% | -178.225M -92.07% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -137.12M 9.43% | -117.201M 14.53% | -63.432M 45.88% | -81.6M -28.64% | -86.7M -6.25% | -68.34M 21.18% | -62.22M 8.96% | -60.18M 3.28% | -57.12M 5.08% | -55.08M 3.57% | |
| Operating Margin | N/A | -1,863.88% | -644.11% | N/A | N/A | -446.67% | -135.56% | -84.29% | -58.95% | -45.00% | |
| EPS YoY % growth | -2.37 13.82% | -1.86 21.52% | N/A 28.71% | -1.33 | -1.38 -3.85% | N/A | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.21 20.67% | -0.21 6.87% | -0.27 -1.56% |
| Revenue Q2Q % growth | -100.00% | -100.00% | -100.00% |
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | -16.149M 7.43% | -14.28M 9.14% | -15.81M -42.91% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
14.47%
Revenue Next 5 Year
47.58%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
KRONOS BIO INC / KRON Forecast FAQ
What is the price target for KRON stock?
7 analysts have analysed KRON and the average price target is 2.3 USD. This implies a price increase of 160.8% is expected in the next year compared to the current price of 0.88.
Can you provide the upcoming earnings date for KRONOS BIO INC?
KRONOS BIO INC (KRON) will report earnings on 2025-08-06, after the market close.
What are the consensus estimates for KRON stock next earnings?
The consensus EPS estimate for the next earnings of KRONOS BIO INC (KRON) is -0.21 USD and the consensus revenue estimate is 0 USD.
Can you provide the expected long term growth rate for KRONOS BIO INC stock?
The expected long term growth rate for KRONOS BIO INC (KRON) is 14.47%.